Recro and Novartis extend pact—News of Note by Eric Palmer Wednesday, February 13, 2019 Novartis has reupped with Recro Pharma's CMO for production of two drugs, plus other news.
Novartis CEO tots up $10M in 2018, with top marks for innovation by Angus Liu Tuesday, February 12, 2019 Vas Narasimhan’s 2018 take-home pay suffered on bottom-of-the-barrel shareholder returns over three years, compared with its Big Pharma rivals.
Doctor payments drove scripts for cancer drugs: study by Arlene Weintraub Friday, February 8, 2019 A new study suggests that the consistency of payments from drugmakers to doctors matters the most when it comes to swaying prescribing habits.
Big Pharma CEOs give thumbs-up to Trump's rebate overhaul by Eric Sagonowsky Thursday, February 7, 2019 Sweep out drug rebates for patient discounts instead? Supply chain players hate the idea, but Big Pharma CEOs are all over it.
Manufacturing cuts likely in remake of Sandoz by Eric Palmer Friday, February 1, 2019 The Sandoz manufacturing network will be further 'optimized' as Novartis turns Sandoz into an autonomous unit in the next 18 months.
Novartis changes NICE's mind on CAR-T Kymriah by Carly Helfand Thursday, January 31, 2019 Payer coverage is key to Novartis’ plan to get Kymriah going, and the company is going to be getting some more of that.
Senate bill proposes 'annuity' payments for pricey treatments by Arlene Weintraub Thursday, January 31, 2019 Two senators have introduced a bill designed to encourage deals that would allow insurers to spread payments for expensive therapies over time.
Botox can hold its own in growing migraine field, Allergan says by Eric Sagonowsky Thursday, January 31, 2019 Despite new competition from CGRP migraine prevention drugs, Allergan executives contend Botox can continue to grow.
Novartis expects a parade to blockbusterland behind Entresto by Angus Liu Wednesday, January 30, 2019 It's been a long slog through a sluggish launch, but Novartis' highly anticipated heart drug Entresto has finally reached blockbuster status.
Alternative payment models to ‘reset the paradigm’: Novartis by Arlene Weintraub Tuesday, January 29, 2019 Novartis figures biopharma companies both large and small will need to embrace alternative payment models for pricey gene and cell therapies.